In this previous work, we described that silibinin interacts with the hydrophobic sites of the catalytic centre of pancreatic lipase in a similar way that orlistat does, which suggests that silibinin has the potential as a complement to dietary therapy for the treatment of obesity [11]. Here, PNLIP is linked to obesity disorder.